Robert Blum
speaker
321 appearances
1 recordings
1 series
first heard Feb 2026
last heard 3 Feb
Robert Blum’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.
Appearances
head to head as was enabling of a best in class drug rooted similarly in biopharmaceutical innovation towards a specialty model.
And I'd say there are episodic and intermittent examples of this, but for which they are farther and fewer in between when you look in the rearview mirror.
And I do think with advances in genetic medicine and specialty cardiology, cytokinetics is one of now several companies that are aiming towards the same objective.
It requires advances not only in biology, but also how we think about accessing and deploying capital and building sales and marketing infrastructure that enable a higher return on investment and shareholder equity, as I think is becoming more common in cardiology.
Cardiology for decades has represented the leading cause of death in the United States.
Heart failure, the leading reason why patients in the United States are hospitalized.
And over the 80s and 90s and into the 2000s,
We've seen dents in how we can treat certain acute cardiovascular conditions, like in the area of thrombolytics and thrombosis associated with heart attacks and stroke.
But now we're seeing how there are new medicines that act directly on
the heart itself, and less on downstream consequences of heart disease.
And that's affording a new way of thinking about specialty cardiology, as you're pointing out.
And cytokinetics is anchored in that kind of science, as I'm sure we'll talk about today.
Yes, exactly.
So if you look at the drugs we used in cardiology in the 80s and the 90s and subsequent, many of them were acting on the vasculature.
Many of them were operating on consequences of impaired cardiac function.
Now we understand a lot more about the etiology, the pathophysiology of cardiac disease, and we can treat it at its root cause, which is cardiac muscle.
And that's where I think cytokinetics has been a pioneer and a leader, as we understand, hopefully better than anyone else, what's underlying cardiac dysfunction and impairment.
Your heart is fundamentally a pump.
It's made up of cardiac myocytes and cardiac muscle.
And cytokinetics has been focused to ways of addressing either hypercontractility or hypocontractility now for many years.
Showing 21–40 of 321 · page 2 of 17
← Previous
Next →